Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Multiple Sclerosis

  Free Subscription


14.04.2020

1 Can J Neurol Sci
1 Immunol Cell Biol
1 Int J Neurosci
1 J Neurol
2 J Neurol Sci
3 Mult Scler
1 Nat Rev Neurol
1 PLoS Genet
4 PLoS One
2 Proc Natl Acad Sci U S A
3 Rev Neurol (Paris)


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Can J Neurol Sci

  1. SASIKUMAR S, Roy-Hewitson C, Geenen C, Robinson D, et al
    Recurrent Abducens Palsy in Relapsing-Remitting Multiple Sclerosis.
    Can J Neurol Sci. 2020 Apr 7:1-6. doi: 10.1017/cjn.2020.
    PubMed        


    Immunol Cell Biol

  2. CARSTENSEN M, Christensen T, Stilund M, Moller HJ, et al
    Activated monocytes and markers of inflammation in newly diagnosed multiple sclerosis.
    Immunol Cell Biol. 2020 Apr 6. doi: 10.1111/imcb.12337.
    PubMed         Abstract available


    Int J Neurosci

  3. MOUSAVI-SHIRAZI-FARD Z, Mazloom Z, Izadi S, Fararouei M, et al
    The effects of modified anti-inflammatory diet on fatigue, quality of life,and inflammatory biomarkers in relapsing-remitting multiple sclerosis patients: A randomized clinical trial.
    Int J Neurosci. 2020 Apr 6:1-12. doi: 10.1080/00207454.2020.1750398.
    PubMed         Abstract available


    J Neurol

  4. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    J Neurol. 2020 Apr 3. pii: 10.1007/s00415-020-09811.
    PubMed         Abstract available


    J Neurol Sci

  5. CUELLO JP, Martinez Gines ML, Tejeda-Velarde A, Medina Heras S, et al
    Cytokine profile during pregnancy predicts relapses during pregnancy and postpartum in multiple sclerosis.
    J Neurol Sci. 2020;414:116811.
    PubMed         Abstract available

  6. FUKUMOTO S, Nakamura Y, Watanabe M, Isobe N, et al
    Risk HLA-DRB1 alleles differentially influence brain and lesion volumes in Japanese patients with multiple sclerosis.
    J Neurol Sci. 2020;413:116768.
    PubMed         Abstract available


    Mult Scler

  7. BELBASIS L, Bellou V, Evangelou E, Tzoulaki I, et al
    Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies.
    Mult Scler. 2020;26:397-404.
    PubMed         Abstract available

  8. YUSUF F, Wijnands JM, Kingwell E, Zhu F, et al
    Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome.
    Mult Scler. 2020 Apr 6:1352458520908163. doi: 10.1177/1352458520908163.
    PubMed         Abstract available

  9. UHER T, McComb M, Galkin S, Srpova B, et al
    Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis.
    Mult Scler. 2020 Apr 7:1352458520912379. doi: 10.1177/1352458520912379.
    PubMed         Abstract available


    Nat Rev Neurol

  10. WOOD H
    Trigeminal neuralgia linked to demyelination in multiple sclerosis.
    Nat Rev Neurol. 2020 Apr 3. pii: 10.1038/s41582-020-0356.
    PubMed        


    PLoS Genet


  11. Correction: Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease.
    PLoS Genet. 2020;16:e1008737.
    PubMed         Abstract available


    PLoS One

  12. HASHEMI R, Hosseini-Asl SS, Arefhosseini SR, Morshedi M, et al
    The impact of vitamin D3 intake on inflammatory markers in multiple sclerosis patients and their first-degree relatives.
    PLoS One. 2020;15:e0231145.
    PubMed         Abstract available

  13. MASUDA H, Mori M, Uzawa A, Uchida T, et al
    Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis.
    PLoS One. 2020;15:e0224419.
    PubMed         Abstract available

  14. GIOVANNETTI AM, Quintas R, Tramacere I, Giordano A, et al
    A resilience group training program for people with multiple sclerosis: Results of a pilot single-blind randomized controlled trial and nested qualitative study.
    PLoS One. 2020;15:e0231380.
    PubMed         Abstract available

  15. SILVA T, Fragoso YD, Destro Rodrigues MFS, Gomes AO, et al
    Effects of photobiomodulation on interleukin-10 and nitrites in individuals with relapsing-remitting multiple sclerosis - Randomized clinical trial.
    PLoS One. 2020;15:e0230551.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  16. ZHANG Y, Li X, Ciric B, Curtis MT, et al
    A dual effect of ursolic acid to the treatment of multiple sclerosis through both immunomodulation and direct remyelination.
    Proc Natl Acad Sci U S A. 2020 Apr 6. pii: 2000208117.
    PubMed         Abstract available

  17. CHANG C, Loo CS, Zhao X, Solt LA, et al
    The nuclear receptor REV-ERBalpha modulates Th17 cell-mediated autoimmune disease.
    Proc Natl Acad Sci U S A. 2019 Aug 27. pii: 1907563116.
    PubMed         Abstract available


    Rev Neurol (Paris)

  18. KREMER S
    Should spinal cord MRI be systematically performed for diagnosis and follow-up of multiple sclerosis? No.
    Rev Neurol (Paris). 2020 Apr 4. pii: S0035-3787(20)30497.
    PubMed        

  19. DE SEZE J, Bigaut K
    Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Yes.
    Rev Neurol (Paris). 2020 Apr 4. pii: S0035-3787(20)30493.
    PubMed         Abstract available

  20. OUALLET JC
    Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment.
    Rev Neurol (Paris). 2020 Apr 8. pii: S0035-3787(20)30495.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: